↓ Skip to main content

Michigan Publishing

Article Metrics

Treatment of catastrophic antiphospholipid syndrome

Overview of attention for article published in Current opinion in rheumatology, May 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#20 of 1,179)
  • High Attention Score compared to outputs of the same age (92nd percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

twitter
36 tweeters
facebook
2 Facebook pages

Citations

dimensions_citation
34 Dimensions

Readers on

mendeley
74 Mendeley
Title
Treatment of catastrophic antiphospholipid syndrome
Published in
Current opinion in rheumatology, May 2016
DOI 10.1097/bor.0000000000000269
Pubmed ID
Authors

Nayef M. Kazzaz, W. Joseph McCune, Jason S. Knight

Abstract

Catastrophic antiphospholipid syndrome (CAPS) is a severe manifestation of antiphospholipid syndrome (APS). Although affecting only 1% of patients with APS, the condition is frequently fatal if not recognized and treated early. Here, we will review the current approach to diagnosis and treatment of CAPS. Data from the international 'CAPS registry', spearheaded by the European Forum on Antiphospholipid Antibodies, have improved our understanding of at-risk patients, typical clinical features, and precipitating diagnoses. Current guidelines also continue to support the role of anticoagulants and glucocorticoids as foundation therapy in all patients. Finally, new basic science and case series suggest that novel therapies, such as rituximab and eculizumab, warrant further study. Attention to associated diagnoses, such as infection and systemic lupus erythematosus (SLE), is critical at the time of diagnosis. All patients should be treated with anticoagulants, corticosteroids, and possibly plasma exchange. In patients with SLE, cyclophosphamide should also be considered. In refractory or relapsing cases, new therapies, such as rituximab and possibly eculizumab, may be options, but need further study.

Twitter Demographics

The data shown below were collected from the profiles of 36 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 74 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Japan 1 1%
Malaysia 1 1%
United States 1 1%
Brazil 1 1%
Unknown 70 95%

Demographic breakdown

Readers by professional status Count As %
Researcher 13 18%
Other 12 16%
Student > Bachelor 9 12%
Professor 7 9%
Student > Postgraduate 7 9%
Other 15 20%
Unknown 11 15%
Readers by discipline Count As %
Medicine and Dentistry 47 64%
Biochemistry, Genetics and Molecular Biology 4 5%
Chemistry 2 3%
Immunology and Microbiology 1 1%
Agricultural and Biological Sciences 1 1%
Other 4 5%
Unknown 15 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 23. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 September 2020.
All research outputs
#908,082
of 15,911,777 outputs
Outputs from Current opinion in rheumatology
#20
of 1,179 outputs
Outputs of similar age
#21,446
of 268,486 outputs
Outputs of similar age from Current opinion in rheumatology
#1
of 14 outputs
Altmetric has tracked 15,911,777 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,179 research outputs from this source. They receive a mean Attention Score of 4.2. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 268,486 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.